BASF's Twin Catalysts: A Long-Awaited FDA Nod and a €7.7bn Coatings Disposal

BASF gains exclusive US sunscreen approval, first since 1999, and advances 7.7bn euro portfolio revamp; stock lags awaiting operational proof.

Investors have been given two very different reasons to reassess BASF this month. On one side, a historic breakthrough in the US sunscreen market unlocks a new revenue stream for the chemicals giant. On the other, the final details of a massive portfolio reshuffle are falling into place. Both developments underscore a company in motion — but the stock has yet to reward the narrative.

The US Food and Drug Administration cleared the UV filter Bemotrizinol, sold by BASF under the brand Tinosorb S, on 12 June. It is the first new active ingredient approved for sunscreens in the United States since 1999, a regulatory drought that had kept the world’s largest cosmetics market effectively closed to modern formulations. BASF now holds an exclusive competitive edge in North America for a molecule prized by the industry for its broad-spectrum protection and photostability. The approval strengthens the Nutrition & Care segment at a time when the group is leaning into high-margin specialty ingredients as part of its green transformation pitch.

Equally transformative is the progress on the structural overhaul. The sale of BASF’s automotive coatings business to Carlyle and the Qatar Investment Authority carries a headline transaction value of €7.7bn. The group will retain a 40% stake and expects a pre-tax cash inflow of roughly €5.8bn. Closing is scheduled for the second quarter of 2026, pending regulatory sign-offs. In parallel, the planned spin-off and IPO of the agricultural solutions division is on track for a Frankfurt listing in 2027, structured as a European Company (Societas Europaea). BASF intends to remain the majority shareholder.

These are no longer aspirational announcements. The deals are live, the processes are running. Yet the market has largely priced them in and now waits for operational proof. The share closed at €49.35, a level that leaves it more than 10% below its April peak and 8.62% lower on a one-month view. The stock sits beneath its 50-day moving average of €52.14 and crossed below the 100-day line in early June — a technical caution flag for short-term traders. The relative strength index of 41.6 suggests weakness, though not yet oversold territory. Year to date, the shares still show a gain of just over 10%, so the broader recovery trend remains intact, if stalled.

On the cost front, BASF has raised its annual savings target to €2.3bn from a prior €2.1bn. The programme is delivering, but cost discipline alone cannot offset a demand environment that a Goldman Sachs analyst recently described as deteriorating “more sharply and more quickly” than anticipated. Chinese producers are leveraging feedstock flexibility to grab market share in Europe, while US tariffs are rerouting global trade flows and intensifying competition in regions with lower import barriers. BASF’s own guidance for 2026 EBITDA sits in a wide range of €6.2bn to €7.0bn — a spread that reflects the prevailing uncertainty.

The FDA approval gives the operational story a fresh catalyst that does not depend on the broader economic cycle. Tinosorb S addresses a pent-up need in the US cosmetics industry, and BASF can now convert the regulatory green light into revenue growth. That dovetails neatly with the group’s broader ambition to position itself as a preferred partner for sustainable chemistry. Yet the real test remains the core chemicals business. First-half results are due in July, and they will need to show that earnings momentum can hold without the help of special items.

For now, BASF is executing on two fronts: unlocking a long-closed American market and reshaping its portfolio through multibillion-euro transactions. The stock trades in a band between roughly €49 and €52, and a sustained breakout above that range likely requires the operational engine to fire in tandem with the structural changes already underway. The pieces are in place — the proof is still pending.